ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Ireland’s Shire will pay $160 million to acquire SARcode Bioscience, a privately owned ophthalmic drug firm based in Brisbane, Calif. The acquisition will give Shire the dry eye disease agent Lifitegrast, which is in Phase III clinical development. The drug is a small-molecule integrin antagonist designed to block a target in the chronic dry eye inflammation cycle. Shire hopes to launch Lifitegrast in the U.S. as early as 2016. Shire may make additional payments to SARcode shareholders.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X